Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lexicon Pharmaceuticals (LXRX – Research Report) and Allakos ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

The Ministry of Planning and Investment, the Ministry of Foreign Affairs, and FPT Corporation co-hosted a working breakfast ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Bayer (0P6S – Research Report), with a price target of ...

GE HealthCare Technologies, Inc. GEHC is well-poised for growth in the coming quarters, courtesy of its continued focus on ...

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Chantilly, VA] — January 22, 2025 — CORT Business Services, the nation’s leading provider of furniture… If 2024 was any indication of New Wave Energy’s trajectory, 2025 is looking very ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. For the quarter ended December ...

(Bloomberg) -- Bayer AG plans to push pause on some of its pharmaceutical dealmaking ... on Monday on the sidelines of the JPMorgan Healthcare Conference in San Francisco. That marks a reversal ...

Oelrich said there was also no reason to split Bayer, whose businesses span agrochemicals, pharmaceuticals and non-prescription drugs. "We function with three very independent businesses," he said.